{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Diethylnitrosamine", "Inflammation", "Nuclear factor kappa B", "Umbelliferon-\u03b1-d-glucopyranosyl-(2(I)\u21921(II))-\u03b1-Dglucopyranoside"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "28802237", "DateCompleted": {"Year": "2018", "Month": "05", "Day": "31"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "30"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "08", "Day": "10"}], "Language": ["eng"], "ELocationID": ["10.1016/j.biopha.2017.07.047", "S0753-3322(17)32289-8"], "Journal": {"ISSN": "1950-6007", "JournalIssue": {"Volume": "94", "PubDate": {"Year": "2017", "Month": "Oct"}}, "Title": "Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie", "ISOAbbreviation": "Biomed Pharmacother"}, "ArticleTitle": "Umbelliferon-\u03b1-d-glucopyranosyl-(2<sup>I</sup>\u21921<sup>II</sup>)-\u03b1-Dglucopyranoside ameliorates Diethylnitrosamine induced precancerous lesion development in liver via regulation of inflammation, hyperproliferation and antioxidant at pre-clinical stage.", "Pagination": {"StartPage": "834", "EndPage": "842", "MedlinePgn": "834-842"}, "Abstract": {"AbstractText": ["It is well documented that anomalous production of inflammatory proteins linked with most of the toxic expression and genesis of diverse chronic disease including cancer. Diethylnitrosamine (DEN) a well-known hepatotoxin and hepatocarcinogen, can induce oxidative stress and inflammatory reaction in it. Umbelliferone, secondary metabolites, is present in different plants and widely consumed by humans as medicine and food supplements. The aim of the current study was to scrutinize the chemoprotective potential of umbelliferon-\u03b1-d-glucopyranosyl-(2<sup>I</sup>\u21921<sup>II</sup>)-\u03b1-d-glucopyranoside (UFD) against DEN-induced hepatocellular carcinoma (HCC) in experimental rats. Single intraperitoneal injection of DEN (200mg/kg) was used for induction of HCC in rats and rats were grouped and orally treated with UFD (5, 10 and 20mg/kg) dose for 22 weeks. Parameters under investigation included hepatic, non-hepatic enzymes, oxidative stress, pro-inflammatory cytokines, COX-2 and NF-\u03baB level along with histopathological examination in HCC rats. UFD exerted protective effect via reduction of oxidative stress, liver and non-liver parameters in a dose-dependent manner. It also reduced the expression of TNF-\u03b1, IL-1\u03b2, IL-6 and COX-2 in diseased rats. Our result revealed the essential repression of the inflammation cascade through modulation of nuclear factor-kappa B (NF-\u03baB) signaling pathway."], "CopyrightInformation": "Copyright \u00a9 2017 Elsevier Masson SAS. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Product Drug Discovery Laboratory, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, 211007, Uttar Pradesh, India. Electronic address: phvikas@gmail.com."}], "LastName": "Kumar", "ForeName": "Vikas", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Advanced Research in Pharmaceutical Sciences, Microbial and Pharmaceutical Biotechnology Laboratory, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India."}], "LastName": "Bhatt", "ForeName": "Prakash Chandra", "Initials": "PC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Product Drug Discovery Laboratory, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, 211007, Uttar Pradesh, India."}], "LastName": "Rahman", "ForeName": "Mahfoozur", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia."}], "LastName": "Al-Abbasi", "ForeName": "Fahad A", "Initials": "FA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia."}], "LastName": "Anwar", "ForeName": "Firoz", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Bio-organic & Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, 211007, Uttar Pradesh, India."}], "LastName": "Verma", "ForeName": "Amita", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Biomed Pharmacother", "NlmUniqueID": "8213295", "ISSNLinking": "0753-3322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anticarcinogenic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Glucosides"}, {"RegistryNumber": "0", "NameOfSubstance": "NF-kappa B"}, {"RegistryNumber": "0", "NameOfSubstance": "Umbelliferones"}, {"RegistryNumber": "3IQ78TTX1A", "NameOfSubstance": "Diethylnitrosamine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Anticarcinogenic Agents"}, {"QualifierName": ["metabolism"], "DescriptorName": "Antioxidants"}, {"QualifierName": ["prevention & control"], "DescriptorName": "Carcinoma, Hepatocellular"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cytokines"}, {"QualifierName": ["toxicity"], "DescriptorName": "Diethylnitrosamine"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Glucosides"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Inflammation"}, {"QualifierName": [], "DescriptorName": "Injections, Intraperitoneal"}, {"QualifierName": ["prevention & control"], "DescriptorName": "Liver Neoplasms"}, {"QualifierName": ["prevention & control"], "DescriptorName": "Liver Neoplasms, Experimental"}, {"QualifierName": ["metabolism"], "DescriptorName": "NF-kappa B"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Precancerous Conditions"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": ["drug effects"], "DescriptorName": "Signal Transduction"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Umbelliferones"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2017", "Month": "5", "Day": "9"}, {"Year": "2017", "Month": "6", "Day": "22"}, {"Year": "2017", "Month": "7", "Day": "11"}, {"Year": "2017", "Month": "8", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "6", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "8", "Day": "13", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["28802237", "10.1016/j.biopha.2017.07.047", "S0753-3322(17)32289-8"]}}]}